New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.
研究概览
简要总结
Alzheimer's disease (AD) is the most common neurodegenerative disorder afflicting the elderly. Currently, some biochemical tests performed on Cerebrospinal Fluid (CSF) samples have demonstrated to discriminate to some extend between AD and non-AD individuals based on the levels of tau, phospho-tau or Aβ42. We aim to investigate newly identified proteins whose levels increase during the Braak Stages of AD that are accessible in other body fluids such as blood, urine or saliva. The detection of these proteins would allow performing simple tests in case its levels were confirmed to be associated with the AD pathology.
详细描述
We do not desire to provide a more extensive description
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •mild to moderate AD
排除标准
- 未提供
结局指标
主要结局
Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.
时间窗: Up to 1 year
Protein levels will be measured by classical immunoblotting blot analysis and quantified; Classical statistical analyses will be performed in order to detect any significant differences.
次要结局
未报告次要终点
研究者
Prof Dr Jos Tournoy
MD PhD
Universitaire Ziekenhuizen KU Leuven